Key result
During cutaneous surgery, aspirin did not increase bleeding risk, whereas warfarin increased the risk of mild-moderate (RR 3.2; 95% CI 1.4-7.1) and severe bleeding (RR 14.8; 95% CI 2.7-80.4).
Why the study?
Does the use of anticoagulation or anti-platelet drugs increase the risk of bleeding complications in patients undergoing cutaneous surgery?
Population
Patients undergoing cutaneous surgery (10 studies included)
Comparison
Anticoagulation and anti-platelet drugs vs Control group
Design
Meta-analysis
Authors
Loading...
Warfarin triples mild-moderate bleeding risk in cutaneous surgery; leaves open optimal perioperative strategies pending RCTs.
Meta-Analysis
Does the use of anticoagulation or anti-platelet drugs increase the risk of bleeding complications in patients undergoing cutaneous surgery?
Relative Risk: 3.2 (95% CI 1.4–7.1)
Aspirin use during cutaneous surgery does not significantly increase bleeding risk, while warfarin use is associated with an increased risk of bleeding complications, though continuation is generally recommended per internal medicine guidelines.
Nast et al. (2014) conducted a meta-analysis in Cutaneous surgery. Anticoagulation and anti-platelet drugs (aspirin, warfarin) vs. Controls (no anticoagulation) was evaluated on Mild-moderate and severe postsurgical bleeding (RR 3.2, 95% CI 1.4-7.1). During cutaneous surgery, aspirin did not increase bleeding risk, whereas warfarin increased the risk of mild-moderate (RR 3.2; 95% CI 1.4-7.1) and severe bleeding (RR 14.8; 95% CI 2.7-80.4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: